
News from endpoints.news
Media Bias Ratings
Do you diasgree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top endpoints.news News

HealthcareDenifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated statistically significant and clinically meaningful improvement compared to placebo in all primary, key secondary, and secondary endpointsDenifanstat demonstrated a favorable safety and tolerability profileDenifanstat was 98% and 178% more…See the Story
Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints
58% Center coverage: 31 sources

23andMeThe saga surrounding the once-hot DNA testing company 23andMe has taken another unexpected turn. Last month, biotech firm Regeneron purchased the company’s assets—including its genetic database of around 15 million users—for $256 million at a bankruptcy auction, seemingly closing the deal. However, a larger bid from Anne Wojcicki, 23andMe’s co-founder and former CEO, has prompted a second auction. At a court hearing in St. Louis, Mo. yesterday (…See the Story
23andMe to Reopen Bankruptcy Court Auction After Anne Wojcicki Group's ...
69% Left coverage: 13 sources
Clinical Psychologist Explains How ADHD Drugs Work, Addresses Unscientific Harm Concerns
50% Left coverage: 8 sources